In the third objective, we explored whether CDX2 pCTCs can be found in other cancers because currently one major limitation in IE CTCs detection is that only broad-spectrum antibodies are used and therefore detection is not specific to any kind of tumour or tissue system. This evidence concerns the gene CDX2 and neoplasm.